Zika cases detected in Woodlands: What you need to know about the virus
SINGAPORE - Two Zika cases have been confirmed in Woodlands Street 11 and Street 32 on June 19.
The National Environment Agency (NEA) said enhanced surveillance has revealed persistent Zika virus signals in the area, which suggest it is an area with likely Zika transmission. The Zika virus has been found in wastewater or mosquito samples collected in the vicinity of the reported cases.
A check on the NEA website shows that as at June 18, there are no Zika clusters in Singapore.
Here's what you need to know about the virus:
Zika is a viral infection spread mainly through the bite of an infected Aedes species mosquito, which also carries the dengue and chikungunya viruses.
It can be transmitted through sex, transfusion of blood and blood products, or from mother to foetus during pregnancy. There is no noticeable pattern as to when Zika cases tend to peak.
The symptoms of Zika and dengue are similar. The viruses can be differentiated by virological tests.
Only one in five people infected with the virus displays symptoms. The most common symptoms are fever, rash, headache, joint and muscle pain, and red eyes.
The symptoms usually develop between three and 12 days after the mosquito bite and often lasts between four and seven days. Nausea and vomiting may also occur. Individuals who suspect they have contracted Zika should see a doctor quickly, advised NEA.
A reverse transcriptase-polymerase chain reaction (RT-PCR) test uses blood and urine tests to determine the infection. Zika infection in blood can be detected between five and seven days of the onset of symptoms, and in urine within 14 days of the first appearance of symptoms.
Unborn babies are at greatest risk should their mother get infected with the Zika virus.
Between 1 per cent and 10 per cent of women infected during pregnancy give birth to babies with birth defects.
The most common defect is microcephaly where the baby is born with a much smaller head and often a smaller brain that might not have developed properly. Other birth defects include difficulty swallowing, hearing loss, and vision problems and seizures.
Not all babies born with congenital Zika virus will have all of these conditions. Some babies develop long-term health problems later on in their life.
There is no known cure for the Zika virus, but symptoms of the infection can be treated.
To avoid getting infected, people are advised to use mosquito repellant and wear clothing that covers the body, arms and legs.
NEA also advises the public to prevent mosquito breeding by removing stagnant water at home and surrounding areas. Stagnant water in potted plants should also be emptied regularly. Sleeping under mosquito nets and in rooms with wire-mesh screens can also help keep out mosquitoes.
According to the World Health Organisation (WHO), the first notable outbreak of the virus was in 1952. It was first identified in monkeys in Uganda in 1947. WHO declared the virus a public health emergency in 2016. The first imported case of the virus in Singapore was in May 2016. The first local cluster was detected in August 2016 in the Aljunied area, with a total of 298 cases. The outbreak was contained in four weeks.
According to NEA's website, about 72,000 gravitraps are currently deployed across Singapore.
There have been a total of seven laboratory-confirmed Zika cases in Singapore as at June 12, 2025. There were 13 recorded cases in 2024.
There is currently no evidence that suggests pregnant women are more vulnerable to the Zika virus. However, the effects of the infection are more severe should a pregnant woman contract it.
The unborn child can develop a range of birth defects such as microcephaly and other issues later in life.
Zika-associated birth defects are more common in infants born to women with exposure to the virus early in the pregnancy.
The highest risk of Zika-associated birth defects is with infections that occur during the first and second trimesters of the pregnancy.
If a non-pregnant woman contracts the virus, future pregnancies are unlikely to be at risk.
The RT-PCR test, which looks for genetic material of the virus in blood or urine, can be used to determine if a pregnant woman is infected.
If a pregnant woman is tested positive or inconclusive for Zika, she will be referred to a maternal foetal medicine specialist for counselling and management. She will be closely monitored and offered regular foetal ultrasounds. The healthcare professional may suggest amniotic fluid testing.
She should take strict precautions against mosquito bites. There is no need to see a doctor if she is well. If she has symptoms of a possible Zika virus infection, she should seek medical attention immediately and consult an obstetrics and gynaecology doctor.
SOURCES: World Health Organisation, National Environment Agency, Communicable Diseases Agency Singapore, US Centre for Disease Control and Prevention, European Centre for Disease Prevention and Control
Source: The Straits Times © SPH Media Limited. Permission required for reproduction
Discover how to enjoy other premium articles here
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Submit your feedback to help shape the future of pharmacy services
York and North Yorkshire residents are being asked to help shape the future of pharmacy services in their area. Feedback from a previous consultation, on whether the locations, accessibility, and services provided by pharmacies are adequate, have already been used to draw up plans for the future. Those plans, which have been incorporated into the Pharmaceutical Needs Assessment, are the subject of a new 60-day consultation underway from Friday (June 20), with the window for feedback to close on Tuesday, August 19. Following this new consultation, the Humber and North Yorkshire Integrated Care Board will decide how pharmacy services are to be commissioned in York and North Yorkshire. Feedback received so far has influenced decisions on, for example, pharmacy opening hours. The survey, which is predicted to take between ten and 15 minutes to complete, can be accessed at
Yahoo
4 hours ago
- Yahoo
Forget 'biological age' tests — longevity experts are using an $800 under-the-radar blood test to measure aging in real-time
Doctors and scientists are using a blood plasma test to study longevity. The test measures proteins and can tell you about your organ health. This field of proteomics could one day help detect diseases like cancer before they start. Should you have that second cup of coffee? How about a little wine with dinner? And, is yogurt really your superfood? Scientists are getting closer to offering consumers a blood test that could help people make daily decisions about how to eat, drink, and sleep that are more perfectly tailored to their unique biology. The forthcoming tests could also help shape what are arguably far more important health decisions, assessing whether your brain is aging too fast, if your kidneys are OK, or if that supplement or drug you're taking is actually doing any good. It's called an organ age test, more officially (and scientifically) known as "proteomics" — and it's the next hot "biological age" marker that researchers are arguing could be better than all the rest. "If I could just get one clock right now, I'd want to get that clock, and I'd like to see it clinically available in older adults," cardiologist Eric Topol, author of the recent bestseller "Super Agers: An Evidence-Based Approach to Longevity," told Business Insider. Topol said armed with organ age test results, people could become more proactive stewards of their own health, before it's too late. "When we have all these layers of data, it's a whole new day for preventing the disease," Topol said. "You see the relationship with women's hormones. You see the relationship with food and alcohol. You don't ever get that with genes." A test like this isn't available to consumers just yet, but it's already being used by researchers at elite universities and high-end longevity clinics. They hope it can become a tool any doctor could use to assess patient health in the next few years. A startup called Vero, which was spun out of some foundational proteomics research at Stanford University, is hoping to beta test a proteomics product for consumers this year. "Knowing your oldest organ isn't the point; changing the trajectory is," Vero co-founder and CEO Paul Coletta told a crowd gathered at the Near Future Summit in Malibu, California, last month. Coletta told Business Insider Vero's not interested in doing "wealthcare." The company plans to make its test available to consumers for around $200 a pop, at scale. Their draw only requires one vial of blood. The big promise of proteomics is that it could be a more precise real-time tool for tracking important but subtle changes that emerge inside each of us as we age. Genetic testing can measure how our bodies are built, spotting vulnerabilities in a person's DNA that might predispose them to health issues. Standard clinical measurements like a person's weight, blood pressure, or cholesterol readings are a useful proxy for potential health issues. Then there are the increasingly popular "biological age" tests available to consumers at home. Most of those look at "epigenetic changes" — how environmental factors affect our gene expression. Proteomics does something different and new. It measures the product that our bodies make based on all those genetic and environmental inputs: proteins. It offers a live assessment of how your body is running, not just how it's programmed. If validated in the next few years, these tests could become key in early disease detection and prevention. They could help influence all kinds of medical decisions, from big ones like "What drugs should I take?" to little ones like "How does my body respond to caffeine or alcohol?" Some high-end longevity clinics are already forging ahead using proteomics to guide clinical recommendations, albeit cautiously. Dr. Evelyne Bischof, a longevity physician who treats patients worldwide, said she uses proteomic information to guide some of the lifestyle interventions she recommends to her patients. She may suggest a more polyphenol-rich diet to someone who seems to have high inflammation and neuroinflammation based on proteomic test results, or may even suggest they do a little more cognitive training, based on what proteomics says about how their brain is aging. Dr. Andrea Maier, a professor of medicine and functional aging at the National University of Singapore, told BI she uses this measurement all the time in her longevity clinics. For her, it's just a research tool, but if the results of her ongoing studies are decent, she hopes to be able to use it clinically in a few years' time. "We want to know what kind of 'ageotype' a person is, so what type of aging personality are you, not from a mental perspective, but from a physical perspective," Maier said. "It's really discovery at this moment in time, and at the edge of being clinically meaningful." "Once we have that validated tool, we will just add it to our routine testing and we can just tick the box and say, 'I also want to know if this person is a cardiac ager, or a brain ager, or a muscle ager' because now we have a sensitive parameter — protein — which can be added," Maier said. The two big-name proteomics tests are Olink and SOMAscan. For now, their high-end screening costs around $400-$800 per patient. "I'm losing lots of money at the moment because of proteomics for clinical research!" Maier said. Top aging researchers at Stanford and Harvard are pushing the field forward, racing to publish more novel insights about the human proteome. The latest findings from Harvard aging researcher Vadim Gladyshev's lab, published earlier this year, suggest that as we age, each person may even stand to benefit from a slightly different antiaging grocery list. To research this idea, Gladyshev looked at proteins in the blood of more than 50,000 people in the UK, all participants in the UK Biobank who are being regularly tested and studied to learn more about their long-term health. He tracked their daily habits and self-reported routines like diet, occupation, and prescriptions, comparing those details to how each patient's organs were aging. He discovered some surprising connections. Yogurt eating, generally speaking, tended to be associated with better intestinal aging but had relatively no benefit to the arteries. White wine drinking, on the other hand, seemed to potentially confer some small benefit to the arteries while wreaking havoc on the gut. "The main point is that people age in different ways in different organs, and therefore we need to find personalized interventions that would fit that particular person," Gladyshev told BI. "Through measuring proteins, you assess the age of different organs and you say, 'OK, this person is old in this artery.'" For now, there's too much noise in the data to do more. Dr. Pal Pacher, a senior investigator at the National Institute on Alcohol Abuse and Alcoholism who studies organ aging and injuries, told BI that proteomics is simply not ready for clinical use yet. There's just too much noise in the data. But he imagines a future where a more sophisticated protein clock could help link up which people may be most vulnerable to diseases like early cancer, kidney disease, and more. (A California-based proteomics company called Seer announced last weekend that it is partnering with Korea University to study whether proteomics can help more quickly diagnose cancer in young people in their 20s and 30s.) "How beautiful could it be in the future?" Maier said. "Instead of three hours of clinical investigation, I would have a tool which guides me much, much better, with more validity towards interventions." Read the original article on Business Insider
Yahoo
5 hours ago
- Yahoo
This Under-the-Radar Healthcare Stock Could Be a Solid Income Play
CVS Health Corporation (NYSE:CVS) is one of the best dividend stocks for a bear market. Even during economic downturns, people continue to rely on medications, essential consumer products, and affordable local healthcare. CVS Health Corporation (NYSE:CVS) serves as a convenient healthcare and retail destination within communities. A row of shelves in a retail pharmacy, demonstrating the variety of drugs and over-the-counter products. The company's overall business remains solid, thanks to its diversified operations and multiple sources of revenue. In recent years, it has expanded its presence in primary care and launched a subsidiary called Cordavis to focus on developing and marketing biosimilar drugs. Its broad reach across communities and wide range of services are key advantages. Lately, higher Medicare usage and increased post-pandemic healthcare costs have impacted the company's revenue and earnings growth. However, CVS Health Corporation (NYSE:CVS) remains profitable and maintains a solid cash position. In the most recent quarter, it reported $4.6 billion in operating cash flow. Looking ahead to 2025, the company has raised its full-year operating cash flow forecast from around $6.5 billion to approximately $7.0 billion. In addition, CVS Health Corporation (NYSE:CVS) appears to have significant room to grow its dividend. With a cash payout ratio of just 30%, even doubling that figure would still leave it within a sustainable range. Due to this strong cash generation, CVS Health Corporation (NYSE:CVS) has maintained its payouts since 1997. Currently, it offers a quarterly dividend of $0.665 per share and has a dividend yield of 3.96%, as of June 17. While we acknowledge the potential of CVS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
